- cafead Sep 01, 2020 at 11:02: AM
via After being bounced by Bristol Myers after its Celgene takeover, Jounce is courting again, this time an early romance with Gilead Sciences.
BMS made the final cut to a longstanding immuno-oncology pact with Jounce back in June, coming as it swung the ax on unwanted projects from its recent Celgene buy.
Jounce is now bouncing back, however with a new deal from Gilead. The biobucks are not as high as the $2.6 billion it originally penned with Celgene, but $685 million is nothing to be sniffed at, and it comes with an $85 million upfront and $35 million equity investment for the biotech.
article source
BMS made the final cut to a longstanding immuno-oncology pact with Jounce back in June, coming as it swung the ax on unwanted projects from its recent Celgene buy.
Jounce is now bouncing back, however with a new deal from Gilead. The biobucks are not as high as the $2.6 billion it originally penned with Celgene, but $685 million is nothing to be sniffed at, and it comes with an $85 million upfront and $35 million equity investment for the biotech.
article source